dc.contributor.author | van Os, Elise Anne | |
dc.contributor.author | Cools, Laura | |
dc.contributor.author | Eysackers, Nathalie | |
dc.contributor.author | Szafranska, Karolina | |
dc.contributor.author | Smout, Ayla | |
dc.contributor.author | Verhulst, Stefaan | |
dc.contributor.author | Reynaert, Hendrik | |
dc.contributor.author | McCourt, Peter Anthony | |
dc.contributor.author | Mannaerts, Inge | |
dc.contributor.author | van Grunsven, Leo A. | |
dc.date.accessioned | 2023-01-16T06:42:54Z | |
dc.date.available | 2023-01-16T06:42:54Z | |
dc.date.issued | 2022-09-28 | |
dc.description.abstract | Chronic liver disease can lead to liver fibrosis and ultimately cirrhosis, which is a significant health burden and a
major cause of death worldwide. Reliable in vitro models are lacking and thus mono-cultures of cell lines are still
used to study liver disease and evaluate candidate anti-fibrotic drugs. We established functional multicellular
liver spheroid (MCLS) cultures using primary mouse hepatocytes, hepatic stellate cells, liver sinusoidal endothelial cells and Kupffer cells. Cell-aggregation and spheroid formation was enhanced with 96-well U-bottom
plates generating over ±700 spheroids from one mouse. Extensive characterization showed that MCLS cultures
contain functional hepatocytes, quiescent stellate cells, fenestrated sinusoidal endothelium and responsive
Kupffer cells that can be maintained for 17 days. MCLS cultures display a fibrotic response upon chronic exposure
to acetaminophen, and present steatosis and fibrosis when challenged with free fatty acid and lipopolysaccharides, reminiscent of non-alcoholic fatty liver disease (NAFLD) stages. Treatment of MCLS cultures with potential
anti-NAFLD drugs such as Elafibranor, Lanifibranor, Pioglitazone and Obeticholic acid shows that all can inhibit
steatosis, but only Elafibranor and especially Lanifibranor inhibit fibrosis. Therefore, primary mouse MCLS
cultures can be used to model acute and chronic liver disease and are suitable for the assessment of anti-NAFLD
drugs. | en_US |
dc.identifier.citation | van Os, Cools, Eysackers, Szafranska, Smout, Verhulst, Reynaert, McCourt, Mannaerts, van Grunsven. Modelling fatty liver disease with mouse liver-derived multicellular spheroids. Biomaterials. 2022;290 | en_US |
dc.identifier.cristinID | FRIDAID 2077120 | |
dc.identifier.doi | 10.1016/j.biomaterials.2022.121817 | |
dc.identifier.issn | 0142-9612 | |
dc.identifier.issn | 1878-5905 | |
dc.identifier.uri | https://hdl.handle.net/10037/28225 | |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.journal | Biomaterials | |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/766181/EU/Super-resolution optical microscopy of nanosized pore dynamics in endothelial cells/DeLiver/ | en_US |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2022 The Author(s) | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) | en_US |
dc.title | Modelling fatty liver disease with mouse liver-derived multicellular spheroids | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |